Abstract: A method for fumigating psyllium husk. The method comprises filling a fumigation chamber with psyllium husk chamber is at least 35% filled with bags of psyllium husk, fumigating the psyllium husk with at least 40 g/m3 of methyl bromide for at least 24 hours, and degassing the chamber for at least 6 hours to form fumigated psyllium husk. The fumigated psyllium husk comprises less than 50 ppm inorganic bromide residue and the fumigated psyllium husk does not comprise an insect infestation or a khapra beetle infestation.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

Abstract: A method for fumigating psyllium husk. The method comprises filling a fumigation chamber with psyllium husk chamber is at least 35% filled with bags of psyllium husk, fumigating the psyllium husk with at least 40 g/m3 of methyl bromide for at least 24 hours, and degassing the chamber for at least 6 hours to form fumigated psyllium husk. The fumigated psyllium husk comprises less than 50 ppm inorganic bromide residue and the fumigated psyllium husk does not comprise an insect infestation or a khapra beetle infestation.

Abstract: A method for fumigating psyllium husk. The method comprises filling a fumigation chamber with psyllium husk chamber is at least 35% filled with bags of psyllium husk, fumigating the psyllium husk with at least 40 g/m3 of methyl bromide for at least 24 hours, and degassing the chamber for at least 6 hours to form fumigated psyllium husk. The fumigated psyllium husk comprises less than 50 ppm inorganic bromide residue and the fumigated psyllium husk does not comprise an insect infestation or a khapra beetle infestation.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health.

Abstract: A method for fumigating psyllium husk. The method comprises filling a fumigation chamber with psyllium husk chamber is at least 35% filled with bags of psyllium husk, fumigating the psyllium husk with at least 40 g/m3 of methyl bromide for at least 24 hours, and degassing the chamber for at least 6 hours to form fumigated psyllium husk. The fumigated psyllium husk comprises less than 50 ppm inorganic bromide residue and the fumigated psyllium husk does not comprise an insect infestation or a khapra beetle infestation.

Abstract: A method for fumigating psyllium husk. The method comprises filling a fumigation chamber with psyllium husk chamber is at least 35% filled with bags of psyllium husk, fumigating the psyllium husk with at least 40 g/m3 of methyl bromide for at least 24 hours, and degassing the chamber for at least 6 hours to form fumigated psyllium husk. The fumigated psyllium husk comprises less than 50 ppm inorganic bromide residue and the fumigated psyllium husk does not comprise an insect infestation or a khapra beetle infestation.

Abstract: A method for measuring of histamine in an epidermis comprising applying an adhesive article to an epithelium of a mammal; allowing for adherence of epithelial cells to the adhesive article; removing the adhesive article from the epithelium of the mammal; preparing the adhesive article using standard laboratory methods for extraction; extracting histamine from the epithelial cells adhered to said adhesive article; measuring histamine from the epithelial cells adhered to said adhesive article; determining the amount of histamine in the epithelial cells as compared to a baseline sample. Further, a method of objectively measuring the perception of itch in mammals and wherein there is a reduction in histamine from a baseline level which is directly proportional to a reduction in an itch perception.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health.

Abstract: In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

Abstract: In various embodiments, provided are methods for formulating compositions for treating and maintaining the quality of skin, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health.

Abstract: A method for measuring of histamine in an epidermis comprising applying an adhesive article to an epithelium of a mammal; allowing for adherence of epithelial cells to the adhesive article; removing the adhesive article from the epithelium of the mammal; preparing the adhesive article using standard laboratory methods for extraction; extracting histamine from the epithelial cells adhered to said adhesive article; measuring histamine from the epithelial cells adhered to said adhesive article; determining the amount of histamine in the epithelial cells as compared to a baseline sample. Further, a method of objectively measuring the perception of itch in mammals and wherein there is a reduction in histamine from a baseline level which is directly proportional to a reduction in an itch perception.

Abstract: The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of chlorite ion in admixture with a pharmaceutically acceptable carrier, said compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and inhibiting the spread into the bloodstream of oral pathogenic bacteria and associated bacterial toxins and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compositions by topically applying to the oral cavity, a safe and effective amount of chlorite ion to promote and/or enhance whole body health in humans and other animals.

Abstract: The present invention relates to topical oral compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, lozenges (including breath mints), dental implements (such as dental floss and tape), and pet care products comprising at least a minimally effective amount of chlorite ion, wherein the pH of the final composition is greater than 7 and the composition is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing diseases and conditions of the oral cavity such as gingivitis, plaque, periodontal disease, herpetic lesions, and infections that may develop following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, and scaling and root planing, in humans and other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.

Abstract: The present invention relates to oral care chewing gum composition comprising at least a minimally effective amount of chlorite ion, wherein preferably the pH of the final composition in use is greater than 7 and level of chlorine dioxide or chlorous acid is less than about 50 ppm, preferably is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating breath malodor in humans or other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.

Abstract: The present invention relates to oral care compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, and lozenges (including breath mints), comprising at least a minimally effective amount of chlorite ion, wherein preferably the pH of the final composition is greater than 7 and level of chlorine dioxide or chlorous acid is less than about 50 ppm, preferably is essentially free of chlorine dioxide or chlorous acid. This invention fuirther relates to a method for treating or preventing gingivitis, plaque, periodontal disease, and/or breath malodor, and/or for the whitening of teeth, in humans or other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.

Abstract: The present invention relates to oral care compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, and lozenges (including breath mints), comprising at least a minimally effective amount of chlorite ion, wherein preferably the pH of the final composition is greater than 7 and level of chlorine dioxide or chlorous acid is less than about 50 ppm, preferably is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing gingivitis, plaque, periodontal disease, and/or breath malodor, and/or for the whitening of teeth, in humans or other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.

Abstract: The present invention relates to oral care compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, and lozenges (including breath mints), comprising at least a minimally effective amount of chlorite ion, wherein preferably the pH of the final composition is greater than 7 and level of chlorine dioxide or chlorous acid is less than about 50 ppm, preferably is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing gingivitis, plaque, periodontal disease, and/or breath malodor, and/or for the whitening of teeth, in humans or other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.